The effect of travoprost on daytime intraocular pressure in normal tension glaucoma: a randomised controlled trial.
OBJECTIVE
To determine the medium-term effect of travoprost on the daytime intraocular pressure (IOP) of patients with normal tension glaucoma (NTG) METHODS: Newly diagnosed NTG patients underwent baseline, daytime, hourly IOP phasing. Patients were randomised to either treatment or no treatment (control). Treatment comprised once daily topical travoprost 0.004%. After 6 months, the participants underwent their second IOP phasing.


RESULTS
Data from 88 participants were analysed-54 were randomised to treatment and 34 to the control group. The mean duration of treatment was 6 months. The average, maximum and minimum diurnal IOPs for treated patients were statistically significantly lower than for control patients at follow-up (p<0.001). When compared with baseline IOP, the travoprost treated group demonstrated a decrease of 16.1%, 13.5% and 16.7% in the average IOP, maximum IOP, and minimum IOP respectively. Of those treated, about one-third achieved a decrease in average IOP of at least 20%; only about one-tenth achieved a reduction of at least 30%.


CONCLUSIONS
Travoprost monotherapy had a sustained hypotensive effect in NTG and achieved a reasonable or good response (>20% reduction in average IOP) in 32.9% of treated eyes. However, in the majority of eyes with NTG, travoprost monotherapy appeared unable to produce the desirable 30% reduction in average IOP.
Norfolk and Norwich University Hospital, Colney Lane, Norwich, UK.
G S
GS
Ang
J P
JP
Kersey
L
L
Shepstone
D C
DC
Broadway
D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002940:Circadian Rhythm; D003008:Cloprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D005901:Glaucoma / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method; D000069557:Travoprost; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D003008:Cloprostenol; D000069557:Travoprost